|
1
|
Rosenberg SA, Restifo NP, Yang JC, Morgan
RA and Dudley ME: Adoptive cell transfer: A clinical path to
effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schmeel FC, Schmeel LC, Gast SM and
Schmidt-Wolf IG: Adoptive immunotherapy strategies with
cytokine-induced killer (CIK) cells in the treatment of
hematological malignancies. Int J Mol Sci. 15:14632–14648. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chung MJ, Park JY, Bang S, Park SW and
Song SY: Phase II clinical trial of ex vivo-expanded
cytokine-induced killer cells therapy in advanced pancreatic
cancer. Cancer Immunol Immunother. 63:939–946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang
N, An X, Yu J, Li H and Ren X: A randomized phase II study of
autologous cytokine-induced killer cells in treatment of
hepatocellular carcinoma. J Clin Immunol. 34:194–203. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pérez-Martínez A, Fernández L, Valentín J,
Martínez-Romera I, Corral MD, Ramírez M, Abad L, Santamaría S,
González-Vicent M, Sirvent S, et al: A phase I/II trial of
interleukin-15-stimulated natural killer cell infusion after
haplo-identical stem cell transplantation for pediatric refractory
solid tumors. Cytotherapy. 17:1594–1603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sakamoto N, Ishikawa T, Kokura S, Okayama
T, Oka K, Ideno M, Sakai F, Kato A, Tanabe M, Enoki T, et al: Phase
I clinical trial of autologous NK cell therapy using novel
expansion method in patients with advanced digestive cancer. J
Transl Med. 13:2772015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bonanno G, Iudicone P, Mariotti A, Procoli
A, Pandolfi A, Fioravanti D, Corallo M, Perillo A, Scambia G,
Pierelli L and Rutella S: Thymoglobulin, interferon-γ and
interleukin-2 efficiently expand cytokine-induced killer (CIK)
cells in clinical-grade cultures. J Transl Med. 8:1292010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou Z, Yu X, Zhang J, Tian Z and Zhang C:
TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell
anti-tumor effects in hepatocellular carcinoma. Cancer Lett.
369:298–306. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Smits EL, Ponsaerts P, Berneman ZN and Van
Tendeloo VF: The use of TLR7 and TLR8 ligands for the enhancement
of cancer immunotherapy. Oncologist. 13:859–875. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Friedberg JW, Kelly JL, Neuberg D,
Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E,
Dalton V, et al: Phase II study of a TLR-9 agonist (1018 ISS) with
rituximab in patients with relapsed or refractory follicular
lymphoma. Br J Haematol. 146:282–291. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dovedi SJ, Melis MH, Wilkinson RW, Adlard
AL, Stratford IJ, Honeychurch J and Illidge TM: Systemic delivery
of a TLR7 agonist in combination with radiation primes durable
antitumor immune responses in mouse models of lymphoma. Blood.
121:251–259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mason KA, Neal R, Hunter N, Ariga H, Ang K
and Milas L: CpG oligodeoxynucleotides are potent enhancers of
radio- and chemoresponses of murine tumors. Radiother Oncol.
80:192–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume
KG and Weissman IL: Use of a SCID mouse/human lymphoma model to
evaluate cytokine-induced killer cells with potent antitumor cell
activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu PH and Negrin RS: A novel population of
expanded human CD3+CD56+ cells derived from T
cells with potent in vivo antitumor activity in mice with severe
combined immunodeficiency. J Immunol. 153:1687–1696.
1994.PubMed/NCBI
|
|
15
|
Hoyle C, Bangs CD, Chang P, Kamel O, Mehta
B and Negrin RS: Expansion of Philadelphia chromosome-negative
CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia
patients: In vitro and in vivo efficacy in severe combined
immunodeficiency disease mice. Blood. 92:3318–3327. 1998.PubMed/NCBI
|
|
16
|
Alvarnas JC, Linn YC, Hope EG and Negrin
RS: Expansion of cytotoxic CD3+ CD56+ cells
from peripheral blood progenitor cells of patients undergoing
autologous hematopoietic cell transplantation. Biol Blood Marrow
Transplant. 7:216–222. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao D, Diao Y, Li W, Gao N, Liu Y, Wang Z,
Jiang W and Jin G: Toll-like receptor 7 inactive ligands enhanced
cytokine induction by conjugation to weak antigens. ChemMedChem.
10:977–980. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pittari G, Filippini P, Gentilcore G,
Grivel JC and Rutella S: Revving up natural killer cells and
cytokine-induced killer cells against hematological malignancies.
Front Immunol. 6:2302015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Schmidt-Wolf IG, Wu YF, Huang SL,
Wei J, Fang J, Huang K and Zhou DH: Optimized protocols for
generation of cord blood-derived cytokine-induced killer/natural
killer cells. Anticancer Res. 30:3493–3499. 2010.PubMed/NCBI
|
|
20
|
Deng QI, Bai X, Lv HR, Xiao X, Zhao MF and
Li YM: Anti-CD20 antibody induces the improvement of
cytokine-induced killer cell activity via the STAT and MAPK/ERK
signaling pathways. Exp Ther Med. 9:1215–1222. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pievani A, Borleri G, Pende D, Moretta L,
Rambaldi A, Golay J and Introna M: Dual-functional capability of
CD3+CD56+ CIK cells, a T-cell subset that
acquires NK function and retains TCR-mediated specific
cytotoxicity. Blood. 118:3301–3310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Abrahamsen IW, Sømme S, Heldal D, Egeland
T, Kvale D and Tjønnfjord GE: Immune reconstitution after
allogeneic stem cell transplantation: The impact of stem cell
source and graft-versus-host disease. Haematologica. 90:86–93.
2005.PubMed/NCBI
|
|
23
|
Xu K, Li C, Pan X and Du B: Study of
relieving graft-versus-host disease by blocking CD137-CD137 ligand
costimulatory pathway in vitro. Int J Hematol. 86:84–90. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee M, Park CS, Lee YR, Im SA, Song S and
Lee CK: Resiquimod, a TLR7/8 agonist, promotes differentiation of
myeloid-derived suppressor cells into macrophages and dendritic
cells. Arch Pharm Res. 37:1234–1240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Richardt-Pargmann D, Wechsler M, Krieg AM,
Vollmer J and Jurk M: Positive T cell co-stimulation by TLR7/8
ligands is dependent on the cellular environment. Immunobiology.
216:12–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ghosh TK, Mickelson DJ, Solberg JC, Lipson
KE, Inglefield JR and Alkan SS: TLR-TLR cross talk in human PBMC
resulting in synergistic and antagonistic regulation of type-1 and
2 interferons, IL-12 and TNF-alpha. Int Immunopharmacol.
7:1111–1121. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Helms MW, Prescher JA, Cao YA, Schaffert S
and Contag CH: IL-12 enhances efficacy and shortens enrichment time
in cytokine-induced killer cell immunotherapy. Cancer Immunol
Immunother. 59:1325–1334. 2010. View Article : Google Scholar : PubMed/NCBI
|
